Codexis earnings release, August 11, 2026
Codexis Reports Second Quarter 2026 Financial Results
Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance
Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO
Synthesis®
Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA
Completed successful equity capital raise of approximately $25 million in net proceeds
REDWOOD CITY, Calif., August 11, 2026 — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.
“I am pleased with the strong financial results reported today for the second quarter of 2026,” stated Alison Moore, PhD, President and Chief
Executive Officer of Codexis. “In May, we presented new data at the TIDES US annual meeting demonstrating how the ECO Synthesis®
Manufacturing Platform enables control over stereochemistry in the manufacture of siRNA compounds which may enhance their potency and product quality. We also demonstrated our technology has the ability to initiate enzymatic RNA synthesis starting from a single nucleotide. In addition, our balance sheet was significantly strengthened by a capital raise of approximately $25 million in net proceeds, completed in July. We have made significant progress in the first half of 2026 in industrializing our ECO Synthesis Manufacturing
Platform, and look forward to continued demonstration of the value of our technology to our customers in the second half.”
Second Quarter and
Recent Business Highlights
Upcoming Milestones
Second Quarter 2026 Financial Highlights
2026 Financial Guidance Reiterated
Codexis reiterated its full-year 2026 financial guidance as follows:
Conference Call and Webcast
Codexis will hold a conference call and webcast today beginning at 4:30 pm ET. A live webcast will be available on the Investors section of the Company website at ir.codexis.com.
The conference call dial-in numbers are
877-705-2976 for domestic callers and
201-689-8798 for international callers.
A telephone recording of the call will be available for 48 hours beginning approximately two hours after the completion of the call by dialing
877-660-6853 for domestic callers or
201-612-7415 for international callers. Please use the passcode 13726635 to access the recording. A webcast replay will be available on the Investors section of the Company website, beginning approximately two hours after the completion of the call.
About Codexis
Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary
CodeEvolver® technology to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis®
Manufacturing Platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, and greater sensitivity in genomic and diagnostic applications.
For more information, visit https://www.codexis.com.
Financial statements
Income Statement
Three Months Ended June 30, — (In Thousands, Except Per Share Amounts)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenues: | Product revenue | 13,218 | 7,380 | 20,409 | 13,439 |
| Revenues: | Research and development revenue | 1,697 | 7,948 | 9,754 | 9,432 |
| Revenues: | Total revenues | 14,915 | 15,328 | 30,163 | 22,871 |
| Costs and operating expenses: | Cost of product revenue | 3,512 | 2,098 | 5,576 | 4,830 |
| Costs and operating expenses: | Research and development | 11,705 | 13,775 | 23,153 | 26,717 |
| Costs and operating expenses: | Selling, general and administrative | 10,927 | 12,317 | 20,706 | 24,672 |
| Costs and operating expenses: | Total costs and operating expenses | 26,144 | 28,190 | 49,435 | 56,219 |
| Costs and operating expenses: | Loss from operations | -11,229 | -12,862 | -19,272 | -33,348 |
| Costs and operating expenses: | Interest income | 535 | 584 | 1,200 | 1,335 |
| Costs and operating expenses: | Interest and other expense, net | -1,301 | -984 | -2,591 | -1,926 |
| Costs and operating expenses: | Loss before income taxes | -11,995 | -13,262 | -20,663 | -33,939 |
| Costs and operating expenses: | Provision for income taxes | 10 | 10 | 46 | 21 |
| Costs and operating expenses: | Net loss | -12,005 | -13,272 | -20,709 | -33,960 |
| Costs and operating expenses: | Net loss per share, basic and diluted | -0.13 | -0.16 | -0.23 | -0.4 |
| Costs and operating expenses: | Weighted average common stock shares used in computing net loss per share, basic and diluted | 91,053 | 85,389 | 90,911 | 83,908 |
Balance Sheet
June 30, 2026 — (In Thousands) (in thousands)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 27,172 | 50,793 |
| Current assets: | Restricted cash, current | 422 | 478 |
| Current assets: | Short-term investments | 27,746 | 27,416 |
| Financial assets: | Accounts receivable | 6,545 | 8,757 |
| Financial assets: | Contract assets | 4,340 | 492 |
| Financial assets: | Unbilled receivables | 805 | 1,480 |
| Financial assets: | Total financial assets | 11,690 | 10,729 |
| Financial assets: | Less: allowances | -43 | -43 |
| Financial assets: | Total financial assets, net | 11,647 | 10,686 |
| Financial assets: | Inventories | 1,602 | 1,817 |
| Financial assets: | Prepaid expenses and other current assets | 3,327 | 5,626 |
| Financial assets: | Total current assets | 71,916 | 96,816 |
| Financial assets: | Restricted cash | 1,612 | 1,612 |
| Financial assets: | Investment in non-marketable equity securities | 2,498 | 2,498 |
| Financial assets: | Right-of-use assets - Operating leases, net | 28,618 | 30,501 |
| Financial assets: | Property and equipment, net | 11,907 | 13,024 |
| Financial assets: | Goodwill | 2,463 | 2,463 |
| Financial assets: | Other non-current assets | 1,041 | 883 |
| Financial assets: | Total assets | 120,055 | 147,797 |
| Current liabilities: | Accounts payable | 2,609 | 1,554 |
| Current liabilities: | Accrued compensation | 6,324 | 11,042 |
| Current liabilities: | Other accrued liabilities | 3,365 | 2,768 |
| Current liabilities: | Current portion of lease obligations - Operating leases | 3,294 | 2,944 |
| Current liabilities: | Current portion of long term debt | 7,057 | |
| Current liabilities: | Deferred revenue | 862 | 7,009 |
| Current liabilities: | Total current liabilities | 23,511 | 25,317 |
| Current liabilities: | Deferred revenue, net of current portion | 360 | |
| Current liabilities: | Long-term lease obligations - Operating leases | 28,417 | 30,159 |
| Current liabilities: | Long-term debt | 33,819 | 40,105 |
| Current liabilities: | Other long-term liabilities | 1,350 | 1,327 |
| Current liabilities: | Total liabilities | 87,097 | 97,268 |
| Stockholders’ equity: | Common stock | 9 | 9 |
| Stockholders’ equity: | Additional paid-in capital | 660,451 | 657,292 |
| Stockholders’ equity: | Accumulated other comprehensive income | -13 | 8 |
| Stockholders’ equity: | Accumulated deficit | -627,489 | -606,780 |
| Stockholders’ equity: | Total stockholders’ equity | 32,958 | 50,529 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 120,055 | 147,797 |
Full release
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”
“contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”
“plan,” “positioned,” “potential,” “predict,” “forecast,” “guidance,” “look forward to,” “milestone,” “on track,” “outlook,”
“project,” “runway,” “seek,” “should,” “suggest,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management. These forward-looking statements include, but are not limited to, statements regarding anticipated milestones, including anticipated product launches by Codexis’ customers, technical milestones, data releases and public announcements related thereto; Codexis’ expectation that its existing cash, cash equivalents and short-term investments will be sufficient to fund its planned operations through the end of 2028, including the expenses associated with the build out of its GMP production facility; Codexis’ 2026 financial guidance, including its revenue and gross margin guidance; the anticipated submission of Codexis’ application for a building permit for its ECO GMP
Manufacturing Center and the timing thereof; the receipt of required permits and approvals for, and the timing, cost and completion of, the retrofit construction of Codexis’ ECO GMP Manufacturing Center, the anticipated commencement of retrofit construction in the second half of 2026 and the achievement of full production capability by the end of 2027, and the intended use of the facility to supply siRNA material for preclinical investigations and Phase 1 clinical trials;
Codexis’ ability to advance partnerships with drug innovators toward clinical stage manufacturing agreements; Codexis’ ability to expand relationships with CDMO partners and to commence an additional strategic partnership by the end of... (todexis’ continued engagement with the FDA’s Emerging Technologies team and the anticipated timing of a meeting with the Agency in the fourth quarter of 2026; and the anticipated benefits, performance, sustainability and commercial potential of Codexis’ ECO Synthesis®
Manufacturing Platform and dsRNA ligase, including the potential effect of enzyme-driven stereoisomer control on the potency and product quality of siRNA compounds and the anticipated level of customer interest in and adoption of Codexis’ technology. The forward-looking statements in this press release are subject to the safe harbor created by these sections, speak only as of the date of this press release, and are qualified by the cautionary statements set forth below. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators and the risk that collaborators may terminate their development programs under their respective license agreements with Codexis; Codexis’ dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets; Codexis’ ability to successfully develop and commercialize new technology and products for its target markets, including its ECO Synthesis® manufacturing platform and dsRNA ligase; the risk that competitors and potential competitors who have greater resources and experience than Codexis may develop products and technologies that make Codexis’ products and technologies obsolete; Codexis’ ability to advance partnerships with drug innovators toward clinical stage manufacturing agreements and to establish strategic partnerships with CDMOs; the timing, cost and successful completion of the retrofit construction of Codexis’ GMP facility and the risk that the facility may not achieve operational readiness on the anticipated timeline; the risk that the FDA or other regulatory authorities may not accept enzymatically synthesized oligonucleotides or that the regulatory pathway for ECO Synthesis-derived products may be longer or more uncertain than anticipated; risks relating to Codexis’ dependence on its GMP facility, and the risk of delays or cost overruns in obtaining permits and approvals, procuring equipment with long lead times, or completing construction; the concentration of Codexis’ revenue in a limited number of contracts and milestones; Codexis’ potential need for additional capital in the future in order to expand its business, the risk that additional capital may not be available on acceptable terms or at all; Codexis’ ability to comply with debt covenants under its loan facility and to satisfy scheduled principal and interest payment obligations, and the effect of the terms of that facility on
Codexis’ liquidity and operating flexibility; risks relating to Codexis’ ability to obtain, maintain, defend and enforce patents, trade secrets and other intellectual property rights covering its technologies, and the risk of intellectual property infringement claims by third parties; Codexis’ dependence on key personnel and its ability to attract and retain qualified employees; Codexis’ reliance on third-party suppliers of nucleotides, reagents and other materials; risks relating to cybersecurity incidents and data integrity; volatility in the market price of Codexis’ common stock and its ability to maintain compliance with Nasdaq listing requirements; Codexis’ ability to accurately forecast financial and operational performance; the impact of market, political and economic conditions on Codexis’ business, financial condition and share price; and the impact of international trade policies, including tariffs, sanctions and trade barriers, on Codexis’ business. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on March 11, 2026, and in Codexis’ Quarterly Report on Form
10-Q for the quarterly period ended June 30, 2026, to be filed with the SEC, in each case including under the caption “Risk Factors,” and in Codexis’ other filings with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Codexis’ results presented in this press release are not necessarily indicative of Codexis’ operating results for any future periods.
For More Information
Investor Contact
Georgia Erbez
(650)
421-8100 ir@codexis.com
Codexis, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In
Thousands, Except Per Share Amounts)
Codexis, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
(In
Thousands)
Codexis, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In
Thousands)